COVID-19 合并难治性重症肌无力：成功治疗 1 例报告
COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome.
机构信息
Department of Neurology, University of Missouri, Columbia, Missouri.
出版信息
J Neuromuscul Dis. 2020;7(3):361-364. doi: 10.3233/JND-200520.
Abstract
This is a brief report of a patient who has refractory Myasthenia Gravis, on multiple long-term immunosuppressive therapies and contracted COVID-19 during this 2020 pandemic. She was quarantined for total of 14 days and recovered successfully without any complications (no myasthenia exacerbation or crisis, no COVID-19 related complications), with no changes to her immunosuppressive therapy. Treatment of MG patients with COVID-19 needs to be tailored to individual patient.
摘要
这是一篇关于一位患有难治性重症肌无力（MG）的患者的简要报告，该患者在 2020 年大流行期间接受了多种长期免疫抑制治疗并感染了 COVID-19。她总共被隔离了 14 天，并成功康复，没有任何并发症（没有肌无力恶化或危象，没有 COVID-19 相关并发症），免疫抑制治疗也没有改变。COVID-19 合并 MG 的治疗需要根据患者个体情况进行调整。
相似文献
1
COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome.
J Neuromuscul Dis. 2020;7(3):361-364. doi: 10.3233/JND-200520.
2
Description of 3 patients with myasthenia gravis and COVID-19.
J Neurol Sci. 2020 Oct 15;417:117053. doi: 10.1016/j.jns.2020.117053. Epub 2020 Jul 22.
3
Clinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection.
Neurology. 2020 Nov 3;95(18):840-843. doi: 10.1212/WNL.0000000000010651. Epub 2020 Aug 14.
4
Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.
J Neurol Sci. 2020 May 15;412:116803. doi: 10.1016/j.jns.2020.116803. Epub 2020 Mar 25.
5
Immunocompromised myasthenia gravis patient not infected with SARS-CoV-2 after close exposure - what is the risk of COVID-19?
Neurol Neurochir Pol. 2020;54(5):481-482. doi: 10.5603/PJNNS.a2020.0072. Epub 2020 Oct 2.
6
[Treatment of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder and Myasthenia Gravis during the COVID-19 Pandemic].
Brain Nerve. 2020 Oct;72(10):1079-1083. doi: 10.11477/mf.1416201652.
7
COVID-19 and generalized Myasthenia Gravis exacerbation: A case report.
Clin Neurol Neurosurg. 2020 Sep;196:106045. doi: 10.1016/j.clineuro.2020.106045. Epub 2020 Jun 25.
8
COVID-19 in patients with myasthenia gravis.
Muscle Nerve. 2020 Aug;62(2):254-258. doi: 10.1002/mus.26918. Epub 2020 May 22.
9
Respiratory dysfunction as first presentation of myasthenia gravis misdiagnosed as COVID-19.
Neurol Sci. 2020 Dec;41(12):3419-3421. doi: 10.1007/s10072-020-04826-3. Epub 2020 Oct 17.
10
Exacerbation of chronic inflammatory demyelinating polyneuropathy in concomitance with COVID-19.
J Neurol Sci. 2020 Nov 15;418:117106. doi: 10.1016/j.jns.2020.117106. Epub 2020 Sep 2.
引用本文的文献
1
Evaluation of Clinical Effects of COVID-19 Infection and Vaccines on Myasthenia Gravis.
Noro Psikiyatr Ars. 2024 Aug 19;67(3):213-220. doi: 10.29399/npa.28418. eCollection 2024.
2
Myasthenia Gravis: Novel Findings and Perspectives on Traditional to Regenerative Therapeutic Interventions.
Aging Dis. 2023 Aug 1;14(4):1070-1092. doi: 10.14336/AD.2022.1215.
3
A comprehensive review of COVID-19 symptoms and treatments in the setting of autoimmune diseases.
Virol J. 2023 Jan 7;20(1):1. doi: 10.1186/s12985-023-01967-7.
4
BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves.
J Neurol. 2022 Dec;269(12):6193-6201. doi: 10.1007/s00415-022-11303-8. Epub 2022 Jul 30.
5
The relationship between myasthenia gravis and COVID-19: a systematic review.
Egypt J Neurol Psychiatr Neurosurg. 2022;58(1):83. doi: 10.1186/s41983-022-00516-3. Epub 2022 Jul 7.
6
A Case of COVID-19 With Myasthenic Crisis.
Cureus. 2022 May 12;14(5):e24936. doi: 10.7759/cureus.24936. eCollection 2022 May.
7
Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients.
J Neurol. 2022 Aug;269(8):3965-3981. doi: 10.1007/s00415-022-11140-9. Epub 2022 May 3.
8
COVID-19 Outcomes in Myasthenia Gravis Patients: Analysis From Electronic Health Records in the United States.
Front Neurol. 2022 Mar 28;13:802559. doi: 10.3389/fneur.2022.802559. eCollection 2022.
9
TREATMENT OF MYASTHENIA GRAVIS PATIENTS WITH COVID-19: REVIEW OF THE LITERATURE.
Acta Clin Croat. 2022 Feb;60(3):496-509. doi: 10.20471/acc.2021.60.03.21.
10
Characteristics, treatment, and outcomes of Myasthenia Gravis in COVID-19 patients: A systematic review.
Clin Neurol Neurosurg. 2022 Feb;213:107140. doi: 10.1016/j.clineuro.2022.107140. Epub 2022 Jan 22.
本文引用的文献
1
Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.
J Neurol Sci. 2020 May 15;412:116803. doi: 10.1016/j.jns.2020.116803. Epub 2020 Mar 25.
2
Myasthenia Gravis and Congenital Myasthenic Syndromes.
Continuum (Minneap Minn). 2019 Dec;25(6):1767-1784. doi: 10.1212/CON.0000000000000800.
3
Factors associated with acute exacerbations of myasthenia gravis.
Muscle Nerve. 2019 Dec;60(6):693-699. doi: 10.1002/mus.26689. Epub 2019 Sep 10.
4
Myasthenia gravis and infectious disease.
J Neurol. 2018 Jun;265(6):1251-1258. doi: 10.1007/s00415-018-8751-9. Epub 2018 Jan 25.
5
Myasthenia Gravis.
N Engl J Med. 2016 Dec 29;375(26):2570-2581. doi: 10.1056/NEJMra1602678.
6
Myasthenia gravis: subgroup classification and therapeutic strategies.
Lancet Neurol. 2015 Oct;14(10):1023-36. doi: 10.1016/S1474-4422(15)00145-3.
7
Myasthenia gravis and risks for comorbidity.
Eur J Neurol. 2015 Jan;22(1):17-23. doi: 10.1111/ene.12599. Epub 2014 Oct 30.
8
T cell-mediated immune response to respiratory coronaviruses.
Immunol Res. 2014 Aug;59(1-3):118-28. doi: 10.1007/s12026-014-8534-z.
9
Myasthenic crisis.
Neurohospitalist. 2011 Jan;1(1):16-22. doi: 10.1177/1941875210382918.
10
Myasthenic crisis.
QJM. 2009 Feb;102(2):97-107. doi: 10.1093/qjmed/hcn152. Epub 2008 Dec 5.
Zotero 插件